Tenax Therapeutics, Inc. Board of Directors

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Mr. Christopher T. Giordano

Mr. Christopher T. Giordano

CEO, President & Director

Dr. Douglas Hay

Dr. Douglas Hay

Senior Vice President of Regulatory Affairs

Mr. Lawrence R. Hoffman CPA, Esq.

Mr. Lawrence R. Hoffman CPA, Esq.

Interim Chief Financial Officer

Mr. Doug Randall

Mr. Doug Randall

Executive Vice President of Commercial & Business Operations

Dr. Stuart Rich M.D.

Dr. Stuart Rich M.D.

Chief Medical Officer & Director

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.